Published in Proc Natl Acad Sci U S A on October 24, 2000
Convergence of Wnt, beta-catenin, and cadherin pathways. Science (2004) 13.13
GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 7.74
Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev (2008) 2.64
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis (2008) 2.30
The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep (2002) 1.93
Physiological regulation of [beta]-catenin stability by Tcf3 and CK1epsilon. J Cell Biol (2001) 1.80
Retracted Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer (2010) 1.69
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
Insulin and wnt1 pathways cooperate to induce reserve cell activation in differentiation and myotube hypertrophy. Mol Biol Cell (2004) 1.52
Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res (2010) 1.51
Winding through the WNT pathway during cellular development and demise. Histol Histopathol (2006) 1.50
The Wnt signaling pathway: aging gracefully as a protectionist? Pharmacol Ther (2008) 1.38
Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses Anchorage-independent growth. Mol Biol Cell (2005) 1.36
Regulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1B-deficient fibroblasts. Mol Cell Biol (2002) 1.27
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol (2013) 1.23
IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition. Cell Commun Signal (2011) 1.17
Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology (2008) 1.11
The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev (2006) 1.08
Growth factor control of bone mass. J Cell Biochem (2009) 1.07
Thyroid hormone-mediated growth and differentiation of growth plate chondrocytes involves IGF-1 modulation of beta-catenin signaling. J Bone Miner Res (2010) 1.06
Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation. Mol Cell Biol (2001) 1.06
Wnt signaling in lung organogenesis. Organogenesis (2008) 1.06
Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status. Cancer Res (2013) 1.06
Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J (2011) 1.05
The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem (2011) 1.02
Insulin-like growth factor-I and bone: lessons from mice and men. Pediatr Nephrol (2008) 1.01
A comparison of epithelial-to-mesenchymal transition and re-epithelialization. Semin Cancer Biol (2012) 1.00
Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9. Endocrinology (2007) 0.99
TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med (2012) 0.97
Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. Carcinogenesis (2009) 0.96
Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett (2003) 0.95
Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension. BMC Med Genomics (2010) 0.93
Nuclear IGF1R is a transcriptional co-activator of LEF1/TCF. EMBO Rep (2012) 0.91
Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis. Korean J Intern Med (2008) 0.91
IGF-I receptor, cell-cell adhesion, tumour development and progression. J Mol Histol (2004) 0.90
Nuclear signaling from cadherin adhesion complexes. Curr Top Dev Biol (2015) 0.90
Canonical Wnt signals combined with suppressed TGFβ/BMP pathways promote renewal of the native human colonic epithelium. Gut (2013) 0.86
The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin. PLoS One (2011) 0.86
MENA is a transcriptional target of the Wnt/beta-catenin pathway. PLoS One (2012) 0.86
Modulation of β-catenin signaling by the inhibitors of MAP kinase, tyrosine kinase, and PI3-kinase pathways. Int J Med Sci (2013) 0.85
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Front Endocrinol (Lausanne) (2015) 0.85
Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee. J Clin Endocrinol Metab (2015) 0.84
IGF-IR in neuroprotection and brain tumors. Front Biosci (Landmark Ed) (2009) 0.83
Suppressor of cytokine signaling-2 gene disruption promotes Apc(Min/+) tumorigenesis and activator protein-1 activation. Am J Pathol (2010) 0.82
The Regulatory Roles of MicroRNAs in Bone Remodeling and Perspectives as Biomarkers in Osteoporosis. Biomed Res Int (2016) 0.82
Role of IGF-I signaling in muscle bone interactions. Bone (2015) 0.80
Autocrine and Paracrine Actions of IGF-I Signaling in Skeletal Development. Bone Res (2013) 0.79
Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective. Ageing Res Rev (2009) 0.79
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway. Cancer Biol Ther (2014) 0.78
Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes. Medicine (Baltimore) (2016) 0.77
IGF-1 Receptor and Adhesion Signaling: An Important Axis in Determining Cancer Cell Phenotype and Therapy Resistance. Front Endocrinol (Lausanne) (2015) 0.77
Serum starvation regulates E-cadherin upregulation via activation of c-Src in non-small-cell lung cancer A549 cells. Am J Physiol Cell Physiol (2014) 0.76
IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer (2017) 0.76
Redistribution of beta-catenin in response to EGF and lithium signalling in human oesophageal squamous carcinoma cell lines. Cancer Cell Int (2003) 0.75
beta-Catenin expression during vascular development and degeneration of avian mesonephros. J Anat (2005) 0.75
Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells. BMC Cancer (2006) 0.75
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. Front Endocrinol (Lausanne) (2017) 0.75
Reduced intestinal tumorigenesis in APCmin mice lacking melanin-concentrating hormone. PLoS One (2012) 0.75
LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis. PLoS One (2017) 0.75
In Vitro Human Umbilical Vein Endothelial Cells Response to Ionic Dissolution Products from Lithium-Containing 45S5 Bioactive Glass. Materials (Basel) (2017) 0.75
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol (2000) 21.15
The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol (2000) 15.78
beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J (1997) 12.97
Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell (1993) 10.36
Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science (1997) 8.99
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J (1998) 7.59
Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A (1995) 7.31
Association of the APC tumor suppressor protein with catenins. Science (1993) 7.17
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6.88
Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J (1993) 5.60
Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol (1994) 5.24
Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem (1998) 5.09
Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol (1994) 4.46
Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem (1997) 4.28
Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin. Mol Cell Biol (1998) 3.79
Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A (1997) 3.79
c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J (1994) 3.58
Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem (1999) 3.53
APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci U S A (2000) 3.41
The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci (1999) 3.37
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. EMBO J (1996) 2.93
Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J Biol Chem (1998) 2.67
Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol (1994) 2.65
Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A (1993) 2.58
Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol (1993) 2.44
The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta (1997) 2.38
Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Curr Opin Cell Biol (1998) 2.34
Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol (1999) 2.17
Exogenous expression of beta-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J Cell Biol (1999) 2.05
Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem (2000) 1.98
Wnt-1 induces growth, cytosolic beta-catenin, and Tcf/Lef transcriptional activation in Rat-1 fibroblasts. Mol Cell Biol (1998) 1.98
Tyrosine phosphorylation and cadherin/catenin function. Bioessays (1997) 1.97
Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol Cell Biol (1999) 1.82
Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem (1999) 1.75
Altered cell adhesion activity by pervanadate due to the dissociation of alpha-catenin from the E-cadherin.catenin complex. J Biol Chem (1998) 1.74
Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol (1999) 1.52
c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun (1995) 1.40
Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest (1997) 1.39
Regulation of complexed and free catenin pools by distinct mechanisms. Differential effects of Wnt-1 and v-Src. J Biol Chem (1997) 1.31
Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci U S A (1999) 1.23
Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br J Cancer (1999) 1.19
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest (1994) 1.19
Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol Endocrinol (1994) 1.14
Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res (1997) 1.11
Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut (1999) 1.11
Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion. Oncogene (1999) 1.10
The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling. J Biol Chem (1999) 1.10
A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res (1996) 1.09
C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor. J Biol Chem (1999) 1.04
Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer (1999) 0.99
Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest (1993) 0.97
Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: involvement of beta-catenin. Anticancer Res (1999) 0.92
Specific cleavage of gamma catenin by caspases during apoptosis. FEBS Lett (1998) 0.92
Insulin-like Growth Factors as Regulators of Cell Motility Signaling Mechanisms. Trends Endocrinol Metab (2008) 0.81
Insulin-like growth factor I receptor messenger RNA in the colon is unchanged during neoplasia. Cancer Invest (1997) 0.80
Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell (1978) 14.82
Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature (1987) 10.21
The number of balanced polymorphisms that can be maintained in a natural population. Genetics (1967) 8.80
Linkage and selection: theoretical analysis of the deterministic two locus random mating model. Genetics (1967) 7.12
Monoclonal antibodies for analysis of the HLA system. Immunol Rev (1979) 6.63
HL-A, immune-response genes, and disease. Lancet (1974) 5.67
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol (1979) 5.06
A migration matrix model for the study of random genetic drift. Genetics (1968) 4.59
Chromosome 5 allele loss in human colorectal carcinomas. Nature (1987) 4.46
HL-A antigens and disease. Statistical and genetical considerations. Tissue Antigens (1974) 4.41
Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol (1984) 4.36
Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A (1999) 4.35
The ABC of APC. Hum Mol Genet (2001) 4.16
Evolutionary significance of the HL-A system. Nature (1972) 4.06
Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer (1981) 3.90
Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A (1997) 3.79
Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet (1992) 3.44
APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci U S A (2000) 3.41
The Eurasian heartland: a continental perspective on Y-chromosome diversity. Proc Natl Acad Sci U S A (2001) 3.38
Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens. Eur J Immunol (1979) 3.27
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Recombination and integration in Bacillus subtilis transformation: involvement of DNA synthesis. J Mol Biol (1965) 3.21
Evolution of sickle variant gene. Lancet (1979) 3.09
Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2. Nature (1978) 2.93
Evolution and function of the HLA system. Br Med Bull (1978) 2.91
The mutation rate and cancer. Proc Natl Acad Sci U S A (1996) 2.73
Histocompatibility (HL-A) antigens associated with systemic lupus erythematosus. A possible genetic predisposition to disease. N Engl J Med (1971) 2.69
CpG island clones from a deletion encompassing the gene for adenomatous polyposis coli. Proc Natl Acad Sci U S A (1989) 2.66
Protein clinical manifestations of primary tumors of the heart. Am J Med (1972) 2.61
Human genetics: the molecular challenge. Cold Spring Harb Symp Quant Biol (1986) 2.54
cDNA clones coding for the heavy chain of human HLA-DR antigen. Proc Natl Acad Sci U S A (1982) 2.51
Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet (1982) 2.51
The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin. Tissue Antigens (1978) 2.40
Integration of deoxyribonuclease-treated DNA in bacillus subtilis transformation. J Gen Physiol (1966) 2.32
The beta2-microglobulin gene is on chromosome 15 and not in the HL-A region. Nature (1975) 2.29
The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc Natl Acad Sci U S A (1998) 2.27
Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science (1996) 2.22
Sequence of an HLA-DR alpha-chain cDNA clone and intron-exon organization of the corresponding gene. Nature (1982) 2.18
Cellular distrubtion, purification, and molecular nature of human Ia antigens. Scand J Immunol (1977) 2.04
Chromosomal localisation of the human homologues to the oncogenes erbA and B. EMBO J (1984) 2.02
A monoclonal antibody that detects HLA-D region antigen in routinely fixed, wax embedded sections of normal and neoplastic lymphoid tissues. J Clin Pathol (1985) 2.00
Assignment of the structural gene for the third component of human complement to chromosome 19. Proc Natl Acad Sci U S A (1982) 2.00
Rapid isolation of human chromosome-specific DNA probes from a somatic cell hybrid. Genomics (1990) 1.99
Genetic factors in Hodgkin's disease: association with a disease-susceptibility locus (DSA) in the HL-A region. Natl Cancer Inst Monogr (1973) 1.98
Nomenclature for factors of the HLA system, 1990. Tissue Antigens (1991) 1.98
Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology (1997) 1.96
Chromosomal localization of human cellular homologues of two viral oncogenes. Nature (1982) 1.96
Six HLA-D region alpha-chain genes on human chromosome 6: polymorphisms and associations of DC alpha-related sequences with DR types. Proc Natl Acad Sci U S A (1984) 1.90
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci U S A (2001) 1.85
Production and characterization of monoclonal antibodies recognizing the alpha-chain subunits of human ia alloantigens. Immunology (1983) 1.85
Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet (2001) 1.81
New genetic model for allelism at histocompatibility and other complex loci: polymorphism for control of gene expression. Transplant Proc (1973) 1.80
Failure of programmed cell death and differentiation as causes of tumors: some simple mathematical models. Proc Natl Acad Sci U S A (1995) 1.78
IGF1R signalling and its inhibition. Endocr Relat Cancer (2006) 1.77
Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions. Lancet (1982) 1.76
APC in the regulation of intestinal crypt fission. J Pathol (1998) 1.73
Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.70
Genetic testing is important in families with a history suggestive of hereditary non-polyposis colorectal cancer even if the Amsterdam criteria are not fulfilled. Br J Surg (1997) 1.66
SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci U S A (2001) 1.65
Molecular structure of human histocompatibility antigens: the HLA-C series. Eur J Immunol (1977) 1.61
Two-dimensional gel analysis of the polypeptides precipitated by a polymorphic HLA-DR1,2,w6 monoclonal antibody: evidence for a third locus. Eur J Immunol (1982) 1.59
Nomenclature for factors of the HLA system, 1991. WHO Nomenclature Committee for factors of the HLA system. Tissue Antigens (1992) 1.58
Nomenclature for factors of the HLA system, 2004. Tissue Antigens (2005) 1.57
Expression of HLA antigens, beta 2-microglobulin and enzymes by human amniotic epithelial cells. Nature (1982) 1.57
Expression of HLA system antigens on placenta. Transplantation (1976) 1.56
Intron splice acceptor site sequence variation in the hereditary non-polyposis colorectal cancer gene hMSH2. Eur J Cancer (1994) 1.54
HLA polymorphism in Israel. 9. An overall comparative analysis. Tissue Antigens (1978) 1.54
Genetic pathways in colorectal and other cancers. Eur J Cancer (1999) 1.53
Monoclonal antibodies to HLA--DRw determinants. Tissue Antigens (1980) 1.49
Genetic pathways in colorectal and other cancers. Eur J Cancer (1999) 1.49
Permanent lymphoid lines from genetically marked lymphocytes: success with lymphocytes recovered from frozen storage. Tissue Antigens (1976) 1.48
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res (1997) 1.47
Chromosome assignment of some human enzyme loci: mitochondrial malate dehydrogenase to 7, mannosephosphate isomerase and pyruvate kinase to 15 and probably, esterase D to 13. Ann Hum Genet (1975) 1.45
A rapid micro method for counting cells "in situ" using a fluorogenic alkaline phosphatase enzyme assay. In Vitro Cell Dev Biol (1989) 1.45
Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int J Cancer (1986) 1.45
Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: the predominant role of hMLH1. Proc Natl Acad Sci U S A (1999) 1.45
Human gene mapping using an X/autosome translocation. Somatic Cell Genet (1976) 1.44
A family study of the association between insulin dependent diabetes mellitus, autoantibodies and the HLA system. Tissue Antigens (1984) 1.44
Genetics and serology of HL-A-linked human Ia antigens. Cold Spring Harb Symp Quant Biol (1977) 1.42
HLA-DP based resistance to Hodgkin's disease. Lancet (1989) 1.42
Defects in mismatch repair occur after APC mutations in the pathogenesis of sporadic colorectal tumours. Hum Mutat (1998) 1.41
Genetics and biochemistry of collagen binding-triggered glandular differentiation in a human colon carcinoma cell line. Proc Natl Acad Sci U S A (1988) 1.40
Nomenclature for factors of the HLA system, 1998. Tissue Antigens (1999) 1.40
Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis. Gut (1994) 1.39
Subcellular separation and molecular nature of human histocompatibility antigens (HL-A). Nature (1974) 1.39
A monoclonal antibody recognizing a human thymus leukemia-like antigen associated with beta 2-microglobulin. Eur J Immunol (1982) 1.39
Medical genetics in China. J Med Genet (1979) 1.39
Changes in cell surface antigen expression during hemopoietic differentiation. Blood (1982) 1.38
Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at APC. Proc Natl Acad Sci U S A (2002) 1.36
Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci U S A (1993) 1.34
CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A (2005) 1.34
DNA mismatch repair genes and colorectal cancer. Gut (2000) 1.34
Nomenclature for factors of the HLA system, 1995. Tissue Antigens (1995) 1.34
Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut (2000) 1.34
Demonstration of two distinct light chains in HLA-DR-associated antigens by two-dimensional gel electrophoresis. Eur J Immunol (1982) 1.33